VSTM Verastem, Inc.
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright Verastem (NASDAQ:VSTM) executives outlined the company’s commercial and clinical priorities at an H.C. Wainwright event, highlighting the launch of its AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated low-grade serous ovarian cancer and the advancement of its KRAS G12D inhibitor, VS-7375, across pancreatic | ||
 Verastem Stock Skyrockets 121% in 3 Months: Here Is Why VSTM shares surge 121% as Avmapki Fakzynja Co-Pack gains commercial traction and VS-7375 advances across key cancer studies. | ||
 Verastem (VSTM) Stock Sees Fair Value Moves Lower As Analysts Cut Revenue Views The average assessed fair value for Verastem has been cut from $16.13 to $14.75, pointing to a moderate reset in price targets. Analysts link this change to a more cautious stance on competition and revenue assumptions, even as many still focus on how Verastem executes on its pipeline and upcoming catalysts. As you read on, you will see how these shifting targets fit into the broader analyst narrative and what to watch as it evolves. Analyst Price Targets don't always capture the full story... | ||
 Verastem (VSTM) Q2 2026 Earnings Call Transcript Revenue surged on CO-PACK launch as cash runway extends into late 2027. | ||
 Verastem Q2 Earnings Call Highlights Verastem (NASDAQ:VSTM) reported second-quarter 2026 net product revenue of $25.1 million from sales of its AVMAPKI FAKZYNJA CO-PACK, as the company said increased new patient starts, refills and physician adoption supported a rebound in commercial performance. The company also reported $15 million | ||
Verastem Inc (VSTM) (Q2 2026) Earnings Call Highlights: Strong Revenue Rebound and Strategic ... Verastem Inc (VSTM) reports $25.1 million in Q2 net product revenues, secures non-dilutive financing, and progresses its KRAS G12D inhibitor program with promising clinical data. | ||
 Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates Verastem (VSTM) delivered earnings and revenue surprises of +23.91% and +73.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.94% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +3.23% and +60.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates Guardant Health (GH) delivered earnings and revenue surprises of -5.00% and +6.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +23.08% and +7.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 RBC Capital Reaffirms Outperform Rating For Verastem (VSTM) Verastem Inc. (NASDAQ:VSTM) is one of the 10 best stocks under $10 that could triple. On July 7, RBC Capital maintained its Outperform rating on Verastem Inc. (NASDAQ:VSTM). The firm reduced the target price from $15 to $14, which still offers a revised upside potential of over 211%. The price target adjustment accompanies the firm’s […] | ||